← Feed
📰 **AstraZeneca: FDA Panel Recommends Truqap Combination For PTEN-Deficient Prostate Cancer **
(RTTNews) - AstraZeneca (AZN) announced that the U.S. FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended approval of Truqap in combination with abiraterone and androgen deprivation therapy (ADT) for patients with PTEN-deficient metastatic hormone-sensitive prostate c...
🔗 https://www.nasdaq.com/articles/astrazeneca-fda-panel-recommends-truqap-combination-pten-deficient-prostate-cancer
#markets #news
(RTTNews) - AstraZeneca (AZN) announced that the U.S. FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended approval of Truqap in combination with abiraterone and androgen deprivation therapy (ADT) for patients with PTEN-deficient metastatic hormone-sensitive prostate c...
🔗 https://www.nasdaq.com/articles/astrazeneca-fda-panel-recommends-truqap-combination-pten-deficient-prostate-cancer
#markets #news